Corcept Investors Face Today’s Lead‑Plaintiff Deadline in Securities Case Over Relacorilant Disclosures

Overview

• Hagens Berman, which issued an alert Tuesday, urged shareholders to meet the April 21 lead‑plaintiff deadline for trades made between Oct. 31, 2024 and Dec. 30, 2025.
• The pending suit, Allegheny County Employees’ Retirement System v. Corcept Therapeutics, is filed in the Northern District of California as No. 26‑cv‑01525.
• Filings say Corcept told investors relacorilant was approaching approval even after FDA meetings in 2024 and 2025 where officials warned the clinical data did not show enough effectiveness.
• Corcept disclosed a Complete Response Letter on Dec. 31, 2025, which means the FDA declined to approve the drug as filed and often asks for more data, and the stock fell from $70.20 to $34.80, erasing about $2.5 billion in value.
• No class has been certified yet, so investors are not represented unless they retain counsel, and law‑firm notices invite investors to seek lead‑plaintiff status without addressing the merits.